Information for cancer patients about oncolytic virus therapy
January 28, 2015
Researchers from The Ottawa Hospital and the University of Ottawa are at the forefront of developing oncolytic virus therapies. This approach uses cancer-fighting viruses to attack cancer cells while leaving healthy cells unharmed.
3 Important Facts about Oncolytic Virus Therapy
- It is still considered experimental and therefore is not available for general use.
- It is only available through clinical trials, which have very specific eligibility criteria.
- Various types of oncolytic virus are currently in clinical trials.
On a special note, we recognize the profound sense of urgency that you and those close to you are experiencing, and we are working as urgently as we can to make promising new cancer therapies more widely available. Although clinical trials require a lot of time and often only accept a small number of patients, they are the only way to develop safe and effective new therapies. We cannot provide experimental therapies outside of approved clinical trials. We thank you for your interest in and continued support of our research.
The table below provides information regarding oncolytic virus trials that are currently open at The Ottawa Hospital.
** We cannot provide experimental therapies outside of approved clinical trials. **
Advanced / metastatic solid tumours
The Maraba virus (MG1MA3) and Adenovirus (AdMA3) trial is for patients with advanced or metastatic solid tumours.
The purpose of the study is to evaluate the safety and effectiveness of the oncolytic virus and vaccine noted above, when given alone and in combination with each other.
Eligibility and other detailsFor more information on this trial, including participating centres and some of the eligibility requirements, please consult the details available at ClinicalTrials.gov (NCT02285816).
Update – February 1, 2016 – The Ottawa Hospital’s wait list for the Maraba trial is temporarily full. No new patients will be screened until more slots become available. Your medical oncologist or gynecologic oncologist at The Ottawa Hospital will be advised when the study will begin to accept additional patients for screening.
If you think you are eligible
You can only request access to an oncolytic virus clinical trial at The Ottawa Hospital if:
- your oncologist thinks you meet the trial’s eligibility requirements,
- you have valid Ontario health coverage, and
- you meet the residency requirement (see 'Important notes' above).
More about clinical trials
For more information about clinical trials and what is involved in participating in a clinical trial, please see our Frequently Asked Questions about Clinical Research.
More about oncolytic virus research at The Ottawa Hospital
- Cancer patients treated in world-first clinical trial of Canadian viral therapy
- The Ottawa Hospital to host $60M national research network for innovative cancer treatments
- Backgrounder: Biotherapeutics for Cancer Treatment (BioCanRX) Network of Centres of Excellence
- Results of world-first viral therapy trial in Ottawa cancer patients published in Nature
- Bolstering the immune system to help fight cancerous tumours
- Cancer research receives major funding boost from Ontario Institute for Cancer Research
- Viruses and bacteria join forces against cancer
- Ottawa researchers discover new cancer-fighting virus